Major order spells growth for Roto-Gro’s cannabis-growing system

By Megan Graham. Published at Mar 16, 2017, in Features

Roto-Gro World Wide Incorporated, a wholly owned subsidiary of Roto-Gro International Limited (ASX:RGI) announced today it had finalised terms with EuroAg Corporation for the supply of 240 Roto-Gro Units over a 12 month period.

The order, pursuant to a Distribution Agreement which is renewable on an annual basis at a minimum of 240 units, represents considerable revenue for Roto-Gro, in excess of A$2.25 million.

Although it should be noted that the industry and companies within it are still in their early stages and therefore investors should seek professional financial advice if considering this stock for their portfolio.

Specifically, the agreement stipulates that EuroAg will purchase a minimum of 240 units within 12 months of the date of the agreement, or 10 months from delivery of the first order. EuroAg has also agreed to drawdown at least 60 units per quarter in order to maintain its distributor status.

The large order demonstrates the strong industry support that exists for Roto-Gro, which is currently in multiple discussions with licensed medical cannabis producers also looking to equip their facilities with Roto-Gro Systems.

It also confirms for investors the company’s leading edge advantage in providing a cost-effective alternative to traditional hydroponic systems. The Roto-Gro’s 420B Model is a rotary hydroponic vertical farming system, with the advanced model – the Roto-Gro 420C – comprising the same components but with the addition of Roto-Gro’s proprietary software system that monitors elements such as room temperature, humidity, CO2 levels, PH levels and more.

These selling points, which the Roto-Gro team has worked diligently to bring to market, amount to a cannabis growing system that’s compact and produces a consistently uniform, high-quality product.

This development adds to the growing list of wins for the company in the short time since it listed on the ASX – and the company has stated there are more sales leads in the pipeline.

Managing Director Michael Carli said: “The Company is primed to capitalise on the immediate opportunity of the rapidly expanding lawful medical cannabis market, with immediate focus on North America, Europe and Australia.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn